Results 61 to 70 of about 796 (164)

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Cenobamate as add-on treatment in ultra-refractory focal epilepsy:Real-world results from The Danish Epilepsy Centre, Dianalund, Denmark

Objectives: At The Danish Epilepsy Centre, Dianalund, Denmark, we aimed to assess the long-term efficacy, tolerability profile, and influence on concomitant antiseizure medications (ASMs) of cenobamate as an add-on treatment in patients with ultra ...
Møller, Rikke S., Rubboli, Guido, Juhl, Stefan, Mieszczanek, Katarzyna M., Gjerulfsen, Cathrine E., Spanilá, Lucie, Thygesen, Kristin S., Pavbro, Agnieszka   +7 more
core   +1 more source

Inhibitory Effects of Cenobamate on Multiple Human Cardiac Ion Channels and Possible Arrhythmogenic Consequences

Cenobamate is a novel third-generation antiepileptic drug used for the treatment of focal onset seizures and particularly for multi-drug-resistant epilepsy; it acts on multiple targets: GABAA receptors (EC50 42–194 µM) and persistent neuronal
Andreea Larisa Mateias, Florian Armasescu, Beatrice Mihaela Radu, Alexandru Dan Corlan, Bogdan Amuzescu   +4 more
core   +1 more source

Reduction in emergency room visits with cenobamate in pharmaco-resistant epilepsy: an observational study

Objective: Cenobamate (Xcopri) is an antiepileptic drug introduced in Israel in July 2023 that has shown promise in reducing seizure frequency in patients with focal seizures.This study aims to evaluate the real-world effectiveness and safety of ...
Aida Hleihil, Felix Benninger, Gal Khazin, Ilan Goldberg, Nir Hersh   +4 more
core   +1 more source

The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil. [PDF]

CNS Drugs
Löscher W, White HS, Klein P.
europepmc   +1 more source

Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies. [PDF]

Front Pharmacol
d'Orsi G, Di Claudio MT, Cafaro A, Barco S, Robustella M, Locatelli N, Liantonio A, Imbrici P, Ciavarella G, Rinaldi A, Fania G, Costantino U, Carella M, Cangemi G, Miscio G.   +14 more
europepmc   +1 more source

Real-World Use of Cenobamate in Paediatric Drug-Resistant Epilepsy: Long-Term Efficacy, Safety, and Co-Medication Adjustment. [PDF]

Eur J Neurol
Pisano T, Pisano T, Balestrini S, Boncristiano A, Caini S, Lombardini M, Scuma E, Cavallin M, Bartolini L, Pellacani S, Barba C, Guerrini R.   +11 more
europepmc   +1 more source

Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study

Introduction Despite new anti-seizure medications (ASMs) being introduced into clinical practice, about one-third of people with epilepsy do not reach seizure control.
Federica Ranzato, Carlo Di Bonaventura, Michela Procaccini, Gabriele Camattari, Alessandra Ori, Nathalie Falsetto, Valentina Villano, Simona Lattanzi, Giovanni Assenza, Paolo Bonanni, Antonio Gambardella, Giancarlo Di Gennaro, on behalf of the BLESS Study Group, Elena Tartara   +13 more
core   +1 more source

Adjunctive Use of Cenobamate in Paediatric Drug-Resistant Epilepsy: A Real-World, Single-Centre Experience. [PDF]

J Clin Med
Oleksy B, Lipiec A, Goszczańska-Ciuchta A, Żebrowska J, Bosak M, Kuźniar-Pałka A, Mazurkiewicz H, Lipińska E, Mazurczak T, Stawicka E.   +9 more
europepmc   +1 more source